Personalization of External Beam Radiation Therapy in Localised Tumours
NCT ID: NCT07047495
Last Updated: 2025-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
35 participants
OBSERVATIONAL
2025-07-31
2030-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Within the prospective study, biological specimens from patients undergoing in-room biopsy before RT, will be collected. Histological evaluation and cell culture (and organoid preparation) will be conducted, and samples/organoids will be irradiated with RT for biological validation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
NCT01913717
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
NCT05936736
Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer
NCT02672449
Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate
NCT00585962
Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate
NCT00548600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostate patients
prostate patients undergoing RT
prostate patient
patients with prostate cancer treated with RT at IEO
breast patients
breast patients undergoing RT
breast patients
patients with breast cancer treated with RT at IEO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prostate patient
patients with prostate cancer treated with RT at IEO
breast patients
patients with breast cancer treated with RT at IEO
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical stage T1-T2,N0
* No contraindications to MRI, or metal joint prostheses from knee to shoulder included, or femoral stent.
* Patients aged \>18 years
* Good general condition (ECOG 0-2)
* Expected active treatment (crioablation or surgery or radiotherapy ).
Exclusion Criteria
* Concomitant inflammation of the intestine
* Significant systemic diseases or ongoing oral anticoagulant therapy
* Non-compliance of dose constraints in the treatment plan
* Previous invasive cancer, unless the patient has had no disease for at least 3 years
* Mental disorders that cannot ensure valid informed consent
* Histology other than non-special histotype and non-epithelial tumors (sarcoma, lymphoma)
* Male sex
* High-risk mutation carrier patients
* Bilateral breast cancer
* synchronous distant metastases
* Neoadjuvant therapy
* autoimmune connective tissue diseases
* previous radiotherapy to the chest
* Mental disorders that cannot ensure valid informed consent
* No previous thoracic radiotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giulia Marvaso
Role: PRINCIPAL_INVESTIGATOR
European Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
European Institute of Oncology
Milan, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UID 4631
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.